U.S. Markets closed

Vanguard Total International Bond ETF (BNDX)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
54.66+0.12 (+0.22%)
At close: 4:00PM EDT
People also watch
VWOBVXUSBNDVTIPVEA
Interactive chart
Previous Close54.54
Open54.64
Bid0.00 x
Ask0.00 x
Day's Range54.58 - 54.68
52 Week Range53.56 - 56.22
Volume456,593
Avg. Volume775,487
Net Assets82.26B
NAV54.27
PE Ratio (TTM)N/A
Yield1.84%
YTD Return0.36%
Beta (3y)0.85
Expense Ratio (net)0.12%
Inception Date2013-05-31
Trade prices are not sourced from all markets
  • Do You Know Where Your Global Bond Money Goes?
    Harvest Exchangelast month

    Do You Know Where Your Global Bond Money Goes?

    By Erin Bigley April 25, 2017 More and more investors are globalizing their bond portfolios these days—with good reason. But when it comes to reducing risk, active management is essential. The French presidential election is just one reason. Bond ...

  • Barrons.comlast month

    El-Erian: French Election Could Roil Markets

    Markets are positioned for a relatively high likelihood that Sunday’s first round of voting in France’s closely-watched, two-stage presidential election paves the way for either centrist candidate Emmanuel Macron or conservative Francois Fillon, a former prime minister, to win the second round. An upset could roil global markets, Mohamed El-Erian, chief economic advisor at Pimco parent Allianz, told Barron’s. In the event the second round pits far-right nationalist candidate Marine Le Pen versus Jean-Luc Mélenchon -- what El-Erian describes as a “notable if” -- he says markets would see an immediate spike in volatility. Surveys show a tight race between Le Pen and Macron, with Fillon and Mélenchon not far behind.

  • PR Newswire2 months ago

    BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, approved a grant representing 20% of a NIS 20M budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of BiondVax's universal flu vaccine candidate M-001. The grant is subject to certain terms and conditions including those outlined under the Encouragement of Capital Investment Law 1959. Five completed Phase 1/2 and Phase 2 human clinical trials have shown the vaccine to be safe and immunogenic to multiple flu strains.